Myrexis Retains Investment Bank to Explore Strategic Alternatives

Myrexis, Inc. MYRX, a biotechnology company focused on the development of small molecule therapeutics, today announced that its Board of Directors has retained Stifel Nicolaus Weisel, an investment banking firm, to assist it in reviewing and evaluating a full range of strategic alternatives available to the Company to enhance shareholder value.